60 results
8-K
EX-99.1
ORIC
ORIC Pharmaceuticals Inc
6 May 24
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
4:10pm
, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer … engagement, and a well-tolerated safety profile.
Presented preclinical data at the 2024 AACR Annual Meeting demonstrating superior preclinical drug
S-3ASR
ORIC
ORIC Pharmaceuticals Inc
11 Mar 24
Automatic shelf registration
5:28pm
prediction of greater than 10 hours, robust target engagement and a favorable safety profile. We expect to initiate a combination study of ORIC-944 … properties, including clinical half-life consistent with a preclinical prediction of greater than 10 hours, robust target engagement and a favorable safety
8-K
EX-99.1
om0wibkm cufmlr9s
11 Mar 24
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
4:10pm
8-K
EX-99.1
qyl7lhh b2m35klyx
9 Jan 24
Results of Operations and Financial Condition
9:00am
S-3
5h76uxitl6jghbdaee9g
15 Dec 23
Shelf registration
4:32pm
8-K
EX-99.1
9b2ujy1kcc 8cpntzur
11 Dec 23
Other Events
4:05pm
8-K
EX-99.1
q0e5a0dc
6 Nov 23
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
4:10pm
8-K
EX-99.1
8rm pziotx
23 Oct 23
Other Events
4:07pm
8-K
EX-99.1
othjdjbiqwn7ff
10 Aug 23
ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates
4:11pm
8-K
EX-99.1
28lvw94g
27 Jun 23
ORIC Pharmaceuticals Announces $85 Million Private Placement Financing
6:05am
8-K
EX-99.2
qrup kd2ml6c0hjocxek
21 Dec 22
Other Events
5:25pm
424B5
zxr3 73qfkpyrj
21 Dec 22
Prospectus supplement for primary offering
5:23pm